RxDoctor Payments DataLook up a doctor →

Christy Davis

Family · Jackson, MSNPI 1063662419

Payments from drug & device makers

$208,405in general payments, 2019–2025

Across 1,151 payments — averaging $181.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$164K
  • Rhythm Pharmaceuticals, Inc.$29K
  • Lilly USA, LLC$2K
  • Amgen$2K
  • Abbott$1K
  • AbbVie$1K
  • plus $8K from 44 others

What the payments were for

  • Consulting fees$4500%
  • Speaking & faculty fees$143,53369%
  • Travel & lodging$40,32419%
  • Food & beverage$23,15611%
  • Education$9420%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$208,405 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$545,504
Medicare patients
274
Services billed
32,102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide154$210,336
MounjaroTirzepatide163$186,035
TrulicityDulaglutide48$75,686
Soliqua 100-33Insulin Glargine/Lixisenatide52$52,217
JardianceEmpagliflozin36$37,038
WegovySemaglutide23$30,181
Tresiba Flextouch U-200Insulin Degludec30$24,291
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog22$23,214
Lyumjev Kwikpen U-100Insulin Lispro-Aabc12$10,089
SynthroidLevothyroxine Sodium82$9,111
Novolog FlexpenInsulin Aspart31$5,220
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$3,624
UnithroidLevothyroxine Sodium13$1,983
Tirosint-SolLevothyroxine Sodium12$1,805
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$2,444$261,720211 claims
Novo NordiskOzempic, Wegovy$164,066$240,517177 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$453$52,21752 claims
Boehringer IngelheimJardiance$793$37,03836 claims
AbbVieSynthroid$1,236$9,11182 claims
Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium$406$3,424193 claims
IBSA Pharma Inc.Tirosint-Sol$34$1,80512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.

Other family in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →